The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...

A deal announced Monday will see the U.K. temporarily sidestep levies on Britain-originated drugs by loosening rules that ...

Indiana shows high potential for the state to become the premiere destination to research, commercialize, scale biotechnology ...

The results position Belite, one of the sector’s top-performing companies since 2022, to seek approval of what could be the ...

The startup’s lead prospect stabilizes abnormal proteins in patients with amyloid “light chain” amyloidosis, an approach that ...

Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority ...

The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...

Itvisma, an intrathecal version of Zolgensma, can be used in children, teens and adults to stabilize or improve motor ...

The second round of negotiations cuts spending an aggregate 44% over 2024 list prices as the federal government extends ...

Top executives can steer large pharma companies in many ways. Here are the ones who employees approve of the most.

The layoffs affect Swiss manufacturing facilities. Elsewhere, the FDA pushed back an approval deadline and a mid-stage study ...

In a rapidly heating market, Otsuka is the first to secure FDA clearance for an "anti-APRIL" therapy targeting IgA ...